Controlling the Achillies Heel of all T Cell Directed Therapies; Suppression of IL-2 Mediated Cytokine Release Syndrome by Combination with IL-10
Time: 12:45 pm
day: Conference Day One
Details:
- Discussing the therapies designed to enhance anti-tumor T cell efficacy and how they all share a common liability, the unpredictable induction of cytokine release syndrome (CRS) that is dissociated from efficacy
- Investigating how, independent of the mode of stimulation, activation of T cells results in secretion of IL-2
- Exploring IL-2 receptor binding leads to the induction of IFNg, TNFa, IL-6 and IL-1b, the hallmark proinflammatory cytokines of CRS. The combination of IL-2 with IL-10 protects the induction of IFNg, while suppressing the secretion of TNFa, IL-6 and IL-1b, thereby suppressing IL-2 mediated CRS and reducing toxicity associated with all therapies that
- activate or employ T cells
